Patient characteristics at the time of the first preemptive rituximab treatment
| Characteristics . | N = 92 . |
|---|---|
| Women | 67 (73) |
| Age, y | 42 (33.3-51) |
| Patients with previous iTTP episodes | 37 (40.2) |
| Rituximab during the acute phase | 50 (54.3) |
| Glucocorticoid therapy | 85 (92) |
| Persistence of severe ADAMTS13 deficiency following iTTP episode* | 25 (27) |
| Development of severe ADAMTS13 deficiency during follow-up† | 67 (73) |
| Anti-ADAMTS13 IgG antibody titer, U/mL | 28 (16-48) |
| Characteristics . | N = 92 . |
|---|---|
| Women | 67 (73) |
| Age, y | 42 (33.3-51) |
| Patients with previous iTTP episodes | 37 (40.2) |
| Rituximab during the acute phase | 50 (54.3) |
| Glucocorticoid therapy | 85 (92) |
| Persistence of severe ADAMTS13 deficiency following iTTP episode* | 25 (27) |
| Development of severe ADAMTS13 deficiency during follow-up† | 67 (73) |
| Anti-ADAMTS13 IgG antibody titer, U/mL | 28 (16-48) |
Data are given as median (25th-75th percentile) for quantitative variables and as n (%) for qualitative variables. Severe ADAMTS13 activity was defined as activity <10% (normal range for ADAMTS13 activity: 50%-100%). The positivity threshold for anti-ADAMTS13 immunoglobulin G (IgG) was 12 U/mL, according to the manufacturer’s instructions (Technoclone).
Eight patients received rituximab during the acute phase of the disease.
Forty-two patients received rituximab during the acute phase of the disease.